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LETTER TO THE EDITOR
Breast cancer and the pill
Sir - The updated Royal College of General Practitioner's
study presented in the November issue (Key & Hannaford,
1988) shows results relevant to studies on the possible
association between the pill and breast cancer in southern
Sweden. In studying the tumour biology and prognosis
among pill users versus others, we have already gathered the
following results not citedoin their paper.
Early users of oral contraceptives (OCs) have larger
primary breast tumours than later users and never users
(Olsson et al., 1986, 1987a) and more often axillary metas-
tases (Olsson et al., 1985b). The finding in the RCGP study
of a higher percentage with tumours of greater invasiveness
among women aged 35 and younger at diagnosis who were
ever users supports our results.
The oestrogen and progesterone receptor content are lower
among early users versus later users, who themselves show
lower levels than never users after adjusting for age at
diagnosis (Olsson et al., 1988). This implies more undifferen-
tiated tumours among early users.
The survival of early OC-users is significantly poorer
than later users and never users (Olsson et al., 1987b, 1988),
which also is in accord with findings of the RCGP study in
women younger than 35 years at diagnosis. A number of
studies have assessed the survival of ever users of OCs versus
never users in premenopausal women (Spencer et al., 1978;
Royal College of General Practitioners, 1981; Matthews et
at., 1981; Vessey et al., 1983; Rosner et al., 1985a,b;
Greenberg et al., 1985; Millard et al., 1987; Palshof, 1988).
In these studies in general no adverse effect of ever OC-use
on survival have been detected. Using the same definition,
the RCGP study and our study could not find a significant
poorer survival in ever users versus never users for the whole
patient material of premenopausal women (Kay &
Hannaford, 1988; Olsson et al., 1988). If OC-use increases the
risk of breast cancer especially after early use, as our finding
so far implies in southern Sweden (Olsson et al., 1985a) the
expectation therefore would be that the tumour biology and
the prognosis would be adversely affected especially after
early use, findings that so far seem to be true in our and in
the RCGP study.
Further investigations especially addressing tumour biol-
ogy and prognosis after early use should be given a high
priority. Such studies may help us to better understand
relevant biology of importance for the alleged association.
Yours etc.,
H'akan Olsson' & Jonas Ranstam2
'Department of Oncology,
University Hospital,
Lund, Sweden; and
2Department of Community Health Sciences,
Lund University, Malmo General Hospital,
Malmo, Sweden.
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